Happy New Year, and thank you for continuing to stand with us — even in the face of so much global turmoil and uncertainty.
While 2025 has been difficult for many, hope persists — and progress continues.
It’s been a while since our last update.
We’ve contacted Health Canada and multiple elected officials. We’ve received no response. The silence has been deafening.
But scientific progress hasn’t stood still.
⸻
VYD2311: A New Monoclonal Antibody Moves to Phase 3
Invivyd has initiated the Phase 3 DECLARATION trial for VYD2311, a variant-resistant monoclonal antibody intended as a vaccine alternative for COVID-19 prevention.
This new antibody builds upon Pemgarda (Pemivibart), updated for broader protection against current and emerging variants. It’s designed to offer crucial protection for those who remain at risk — including the immunocompromised.
VYD2311 has also received Fast Track Designation from the U.S. FDA, signaling its potential to fill a critical gap in COVID-19 prevention.
🔬 Learn more:
Press Release — Trial Launch:
Fast Track Designation:
Clinical Trial Listing:
https://www.clinicaltrials.gov/study/NCT07298434
⸻
Trial Eligibility: Not Just for High-Risk Groups
While our petition focuses on the immunocompromised, it’s worth noting that the DECLARATION trial is open to both high-risk and healthy individuals. This helps researchers assess how well VYD2311 works across a wide population.
If you or someone you know is interested, you may wish to inquire about participating in the trial.
But make no mistake: for the immunocompromised in Canada, there is still no access to Pemgarda or any variant-resistant monoclonal antibody. Even as science advances, policy continues to lag behind.
⸻
We’re Still Here. Still Fighting.
This petition remains active because our work isn’t finished.
We continue to push for access to life-saving tools for the most vulnerable.
Every voice matters. Every share helps. We won’t stop until protection is a right — not a privilege.
Thank you for standing with us.
Sign & share:
— Rowan